Motavizumab, A Neutralizing Anti-Respiratory Syncytial Virus (Rsv) Monoclonal Antibody Significantly Modifies The Local And Systemic Cytokine Responses Induced By Rsv In The Mouse Model
2007

Motavizumab Reduces RSV Infection Severity in Mice

Sample size: 8 publication Evidence: moderate

Author Information

Author(s): Asunción Mejías, Susana Chávez-Bueno, Martin B. Raynor, John Connolly, Peter A. Kiener, Hasan S. Jafri, Octavio Ramilo

Primary Institution: University of Texas Southwestern Medical Center at Dallas

Hypothesis

The administration of motavizumab will modify the immune response and reduce disease severity in RSV-infected mice.

Conclusion

Prophylactic administration of motavizumab significantly decreased RSV replication and cytokine responses, preventing clinical disease in mice.

Supporting Evidence

  • Motavizumab significantly reduced RSV replication in treated mice.
  • Lower concentrations of several cytokines were observed in the motavizumab group compared to untreated controls.
  • Clinical disease was completely prevented in mice treated with motavizumab.

Takeaway

This study shows that a special medicine called motavizumab can help mice fight off a virus that makes them sick by lowering the amount of bad stuff in their bodies.

Methodology

BALB/c mice were inoculated with RSV and treated with motavizumab; cytokine levels were measured in bronchoalveolar lavage and serum samples.

Limitations

The study was conducted in a mouse model, which may not fully represent human responses to RSV.

Participant Demographics

Seven-week-old female BALB/c mice.

Statistical Information

P-Value

p<0.05

Confidence Interval

[2.22–2.53]

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1743-422X-4-109

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication